Last $296.74 USD
Change Today -3.40 / -1.13%
Volume 607.2K
REGN On Other Exchanges
Symbol
Exchange
NASDAQ GS
Munich
As of 8:10 PM 04/17/14 All times are local (Market data is delayed by at least 15 minutes).

regeneron pharmaceuticals (REGN) Snapshot

Open
$300.45
Previous Close
$300.14
Day High
$304.96
Day Low
$296.02
52 Week High
03/6/14 - $352.49
52 Week Low
06/24/13 - $206.30
Market Cap
29.5B
Average Volume 10 Days
1.2M
EPS TTM
$3.80
Shares Outstanding
97.9M
EX-Date
--
P/E TM
78.1x
Dividend
--
Dividend Yield
--
Current Stock Chart for REGENERON PHARMACEUTICALS (REGN)

regeneron pharmaceuticals (REGN) Related Businessweek News

View More BusinessWeek News

regeneron pharmaceuticals (REGN) Details

Regeneron Pharmaceuticals, Inc., a biopharmaceutical company, discovers, invents, develops, manufactures, and commercializes medicines for the treatment of serious medical conditions in the United States and internationally. The company offers EYLEA injection for the treatment of neovascular age-related macular degeneration and macular edema; ZALTRAP, an injection for intravenous infusion for the treatment of patients with metastatic colorectal cancer; and ARCALYST, an injection for subcutaneous use for treating cryopyrin-associated periodic syndromes, including familial cold auto-inflammatory syndrome and muckle-wells syndrome in adults and children. Its product candidates in clinical development stage comprise EYLEA for the treatment of DME and macular edema ophthalmologic diseases; and ZALTRAP for oncology. The company’s antibody-based clinical programs include various human monoclonal antibody product candidates, such as REGN88 for rheumatoid arthritis and non-infectious uveitis; REGN727 for low-density lipoprotein cholesterol reduction; REGN668 for atopic dermatitis, asthma, and nasal polyposis; REGN421, REGN910, and REGN1400 for oncology; REGN475 for the treatment of pain; and REGN1033 for skeletal muscle disorders. It is also developing REGN1154, REGN1154, REGN1193, and REGN1908-1909 antibody product candidates, as well as REGN2176-3, an antibody that is co-formulated with EYLEA for use in ophthalmology. The company distributes its products through Rensselaer facilities and third party service providers. It has strategic collaboration with Sanofi to discover, develop, and commercialize human monoclonal antibodies; and license and collaboration agreement with Bayer HealthCare for the development and commercialization of EYLEA outside the United States. The company was founded in 1988 and is headquartered in Tarrytown, New York.

2,340 Employees
Last Reported Date: 02/13/14
Founded in 1988

regeneron pharmaceuticals (REGN) Top Compensated Officers

Co-Founder, Chief Executive Officer, Presiden...
Total Annual Compensation: $3.3M
Chief Scientific Officer, Executive Vice Pres...
Total Annual Compensation: $2.8M
Senior Vice President of Research & Developme...
Total Annual Compensation: $833.9K
Senior Vice President of Commercial
Total Annual Compensation: $796.5K
Senior Vice President of Administration
Total Annual Compensation: $832.4K
Compensation as of Fiscal Year 2012.

regeneron pharmaceuticals (REGN) Key Developments

Regeneron Pharmaceuticals, Inc. Announces Board Changes

Regeneron Pharmaceuticals, Inc. announced that it has elected Robert A. Ingram to its Board of Directors. The company also announced that Dr. Eric Shooter, a co-founder of the company, is retiring from the Board after nearly 26 years of service to the company. The company noted that Ingram was nominated to become a member of the company's Board by Sanofi. Under the terms of an investor agreement between Regeneron and Sanofi, Sanofi gained the right to nominate a single independent director to the company Board of Directors when it reached 20% ownership of the company's total outstanding common stock and Class A stock. Further, Ingram is a General Partner at Hatteras Venture Partners.

Regeneron Pharmaceuticals, Inc. Announces Board Changes

Regeneron Pharmaceuticals, Inc. announced that it has elected Robert A. Ingram to its Board of Directors. Regeneron also announced that Dr. Eric Shooter, a co-founder of the Company, is retiring from the Board after nearly 26 years of service to Regeneron. Mr. Ingram was nominated to become a member of Regeneron's Board by Sanofi. Regeneron also announced that Dr. Eric Shooter, a co-founder of the Company, is retiring from the Board after nearly 26 years of outstanding service to Regeneron. Dr. Shooter has been a Professor at Stanford University School of Medicine since 1968 and was the founding Chairman of the Department of Neurobiology at Stanford University School of Medicine in 1975 and served as its Chairman until 1987.

Sanofi and Regeneron Report Positive Results with Alirocumab from Phase 2 Japanese Study

Sanofi and Regeneron Pharmaceuticals, Inc. announced that the first Phase 2 study with alirocumab, an investigational monoclonal antibody targeting PCSK9 (proprotein convertase subtilisin/kexin type 9), in Japanese patients met its primary endpoint. The results demonstrated that the mean low-density lipoprotein-cholesterol (LDL-C, or "bad" cholesterol) percentage reduction from baseline to week 12, the primary efficacy endpoint of the study, was significantly greater in patients randomized to receive one of three doses of alirocumab administered every other week (Q2W) -- 150 milligrams (mg), 75 mg, and 50 mg, in combination with statin therapy, compared to patients receiving placebo. At Week 12, the mean percentage reduction in LDL-C from baseline in patients receiving alirocumab 50 mg Q2W was 55%, alirocumab 75 mg Q2W was 62% and alirocumab 150 mg Q2W was 72%, compared to 3% in the placebo group (p<0.0001 vs. placebo for all treatment arms). This multicenter, placebo-controlled Phase 2 study randomized approximately 100 patients with LDL-C greater than or equal to 100 mg/dL receiving lipid-modifying therapy. 25 patients per group were randomized to receive one of three doses of alirocumab dosed subcutaneously every other week (Q2W) -- 150 milligrams (mg), 75 mg or 50 mg, or placebo, all in combination with statin therapy. The primary study endpoint was the percentage change in calculated LDL-C from baseline to Week 12. The secondary study endpoints included absolute change in calculated LDL-C from baseline to Week 12 and percent and absolute changes in other lipid parameters at Week 12.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
REGN:US $296.74 USD -3.40

REGN Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Alexion Pharmaceuticals Inc $149.80 USD +0.75
Allergan Inc/United States $133.92 USD +2.46
BioMarin Pharmaceutical Inc $60.89 USD -0.48
Jazz Pharmaceuticals Plc $136.16 USD +0.055
Vertex Pharmaceuticals Inc $64.17 USD -0.22
View Industry Companies
 

Industry Analysis

REGN

Industry Average

Valuation REGN Industry Range
Price/Earnings 77.8x
Price/Sales 13.9x
Price/Book 15.1x
Price/Cash Flow 69.9x
TEV/Sales 13.5x
 | 

Post a JobJobs

View all jobs

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact REGENERON PHARMACEUTICALS, please visit www.regeneron.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.